Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2011 Jun 1;21(11):3452-6. doi: 10.1016/j.bmcl.2011.03.098. Epub 2011 Apr 1.

3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.

Author information

1
Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. michael.soth@roche.com

Abstract

Learnings from previous Roche p38-selective inhibitors were applied to a new fragment hit, which was optimized to a potent, exquisitely selective preclinical lead with a good pharmacokinetic profile.

PMID:
21515047
DOI:
10.1016/j.bmcl.2011.03.098
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center